These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26728536)

  • 21. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
    Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
    J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
    Watanabe R; Okazaki R
    Clin Calcium; 2014 Jan; 24(1):59-67. PubMed ID: 24369281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies.
    Esbrit P; Alcaraz MJ
    Biochem Pharmacol; 2013 May; 85(10):1417-23. PubMed ID: 23500550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Update and perspectives of anabolic therapies for osteoporosis].
    Endo I; Matsumoto T
    Clin Calcium; 2012 Mar; 22(3):327-33. PubMed ID: 22370299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perspectives on osteoporosis therapies.
    Cairoli E; Zhukouskaya VV; Eller-Vainicher C; Chiodini I
    J Endocrinol Invest; 2015 Mar; 38(3):303-11. PubMed ID: 25577263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting sclerostin as potential treatment of osteoporosis.
    Papapoulos SE
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i119-22. PubMed ID: 21339215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological agents in management of osteoporosis.
    Tella SH; Gallagher JC
    Eur J Clin Pharmacol; 2014 Nov; 70(11):1291-301. PubMed ID: 25204309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [[Antiresorptive agents in the treatment of osteoporosis].
    Novak S
    Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin.
    Gatti D; Viapiana O; Adami S; Idolazzi L; Fracassi E; Rossini M
    Bone; 2012 Mar; 50(3):739-42. PubMed ID: 22178539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-resorptive therapies for osteoporosis.
    Reid IR
    Semin Cell Dev Biol; 2008 Oct; 19(5):473-8. PubMed ID: 18760372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
    Miki T; Minamide T
    Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New therapy using bisphosphonate for urolithiasis].
    Yasui T; Niimi K; Hirose M
    Clin Calcium; 2011 Oct; 21(10):1511-5. PubMed ID: 21960237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New bone density conservation agents for osteoporosis under research and development: ED-71].
    Hagino H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():454-8. PubMed ID: 18161148
    [No Abstract]   [Full Text] [Related]  

  • 34. Established and forthcoming drugs for the treatment of osteoporosis.
    Lems WF; Geusens P
    Curr Opin Rheumatol; 2014 May; 26(3):245-51. PubMed ID: 24625372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
    McDonald MM; Reagan MR; Youlten SE; Mohanty ST; Seckinger A; Terry RL; Pettitt JA; Simic MK; Cheng TL; Morse A; Le LMT; Abi-Hanna D; Kramer I; Falank C; Fairfield H; Ghobrial IM; Baldock PA; Little DG; Kneissel M; Vanderkerken K; Bassett JHD; Williams GR; Oyajobi BO; Hose D; Phan TG; Croucher PI
    Blood; 2017 Jun; 129(26):3452-3464. PubMed ID: 28515094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New anti-osteoporotic drugs under development].
    Inoue D
    Nihon Rinsho; 2015 Oct; 73(10):1712-7. PubMed ID: 26529935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.
    Tian X; Jee WS; Li X; Paszty C; Ke HZ
    Bone; 2011 Feb; 48(2):197-201. PubMed ID: 20850580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Regulation of bone metabolism in osteoporosis : novel drugs for osteoporosis in development].
    Jakob F; Genest F; Baron G; Stumpf U; Rudert M; Seefried L
    Unfallchirurg; 2015 Nov; 118(11):925-32. PubMed ID: 26471379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
    Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
    Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
    J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.